Table 2.
Clinical information and serology of ocrelizumab-treated group
| Patient | Sex | Age (years) | Disease duration (years) | EDSS | Vaccine | Test method | Antibody titer (U/ml) | Titer cut-off (U/ml) | Test result | Time vaccine-test (days) | WBC (× 109/l) | Lymphocytes (× 109/l) | CD20 count (%) | Therapy duration (years) | Therapy cycles | Time vaccine-last dose (months) | Previous IS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 50.6 | 13.4 | 5.5 | BNT162b2 | ECLIA | < 0.40 | 0.80 | Negative | 37 | 5.76 | 0.99 | 0.00 | 1.3 | 2 | 4.8 | Yes |
| 2 | F | 30.8 | 6.8 | 1.0 | BNT162b2 | CMIA | 2.80 | 50.00 | Negative | 33 | NA | NA | NA | 2.1 | 4 | 2.4 | No |
| 3 | F | 40.0 | 14.0 | 3.5 | BNT162b2 | CMIA | 0.30 | NA | Negative | 25 | 4.64 | 1.22 | 1.00 | 2.5 | 4 | 5.0 | No |
| 4 | F | 41.1 | 22.4 | 5.5 | BNT162b2 | DELFIA | 21.00 | 1.20 | Positive | 61 | NA | NA | NA | 2.0 | 2 | 8.2 | Yes |
| 5 | F | 50.8 | 8.3 | 6.5 | BNT162b2 | ECLIA | 98.50 | 0.80 | Positive | 19 | 6.37 | 1.60 | 11.10 | 3.4 | 5 | 5.4 | Yes |
| 6 | M | 57.1 | 8.4 | 5.0 | BNT162b2 | ECLIA | 238.00 | 0.80 | Positive | 31 | 6.30 | 1.30 | 2.10 | 3.4 | 6 | 5.0 | Yes |
| 7 | F | 28.0 | 3.4 | 1.5 | BNT162b2 | CLIA | 0.05 | 1.00 | Negative | 31 | 6.60 | 1.90 | 0.03 | 2.4 | 4 | 3.1 | No |
| 8 | F | 61.3 | 11.0 | 6.0 | BNT162b2 | ECLIA | 0.11 | 1.10 | Negative | 34 | 5.28 | 2.35 | 0.10 | 3.2 | 6 | 5.8 | No |
| 9 | F | 46.6 | 26.0 | 6.5 | BNT162b2 | CLIA | 0.07 | 10.00 | Negative | 66 | NA | NA | NA | 2.7 | 6 | 2.8 | Yes |
| 10 | M | 32.3 | 14.0 | 6.5 | BNT162b2 | ECLIA | < 0.40 | 0.80 | Negative | 30 | 9.20 | 2.20 | 0.00 | 2.5 | 5 | 5.0 | No |
| 11 | M | 23.0 | 6.1 | 2.5 | mRNA-1273 | ECLIA | < 0.40 | 0.80 | Negative | 42 | 6.50 | 2.30 | 0.50 | 2.9 | 5 | 4.6 | No |
| 12 | F | 56.3 | 1.3 | 4.5 | BNT162b2 | CLIA | 65.90 | 15.00 | Positive | 19 | 4.20 | 1.60 | 0.50 | 0.0 | 1 | 3.5 | No |
| 13 | M | 43.4 | 4.3 | 4.5 | BNT162b2 | ECLIA | < 0.40 | 0.80 | Negative | 18 | 5.80 | 1.20 | 0.00 | 2.7 | 5 | 5.9 | No |
| 14 | M | 36.8 | 10.9 | 3.5 | BNT162b2 | ECLIA | 22.40 | 0.80 | Positive | 21 | 5.49 | 1.18 | 0.03 | 2.1 | 4 | 5.9 | No |
| 15 | F | 64.1 | 19.5 | 3.0 | BNT162b2 | CMIA | 155.00 | 33.80 | Positive | 21 | 3.96 | 1.12 | 0.04 | 2.1 | 4 | 5.5 | Yes |
| 16 | M | 43.2 | 25.2 | 4.0 | BNT162b2 | CMIA | < 2.20 | 22.00 | Negative | 28 | 4.33 | 1.14 | 0.03 | 2.2 | 4 | 4.2 | Yes |
WBC white blood cells count, IS immunosuppressants—i.e. cyclophosphamide, mitoxantrone, ECLIA electrochemiluminescence immunoassay, CLIA chemiluminescence immunoassay, CMIA chemiluminescence microparticle immunoassay, DELFIA dissociation-enhanced lanthanide fluorescent immunoassay